For these reasons, targeting AFP could be a new therapeutic strategy in the treatment of HCC, and an ongoing trial is evaluating the efficacy of T cells’ reprogramming against AFP in AFP-expressing HCC patients [66]. The gene discussed is AFP; the disease is hepatocellular carcinoma.